Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trialSandro Pignata, I. L. Ray-Coquard, Elena Zafarana et al.|The Lancet Oncology|2021Cited by 148
Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trialValentina Guarneri, PierFranco Conte, Maria Vittoria Dieci et al.|European Journal of Cancer|2021Cited by 42
Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical reviewFederica Miglietta, Valentina Guarneri, Alessandra Fabi et al.|Cancer Treatment Reviews|2023Cited by 13
Ten-year update of HOBOE phase III trial comparing triptorelin plus either tamoxifen or letrozole or zoledronic acid + letrozole in premenopausal hormone receptor-positive early breast cancer patientsAdriano Gravina, Federica Perrone, P. Gargiulo et al.|ESMO Open|2025Cited by 8
Abstract P5-01-07: Bioitalee - Biomarker analysis on liquid biopsies of patients treated with ribociclib and letrozole as first-line therapy for advanced breast cancer (aBC) (NCT03439046)Michelino De Laurentiis, Grazia Arpino, Luca Malorni et al.|Cancer Research|2020Cited by 6